BlackRock Investment Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

BlackRock Investment Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$406K	Hold	159,176	–	–	﹤0.01%	3097
2016 Q3	$492K	Sell	159,176 -729	-0.5%	-$2.27K	﹤0.01%	3058
2016 Q2	$513K	Buy	159,905 +10,473	+7%	+$38.4K	﹤0.01%	3057
2016 Q1	$463K	Buy	149,432 +939	+0.6%	+$3.07K	﹤0.01%	2931
2015 Q4	$595K	Buy	148,493 +187	+0.1%	+$861	﹤0.01%	2929
2015 Q3	$679K	Sell	148,306 -1,007	-0.7%	-$5.27K	﹤0.01%	2882
2015 Q2	$775K	Buy	149,313 +39,890	+36%	+$239K	﹤0.01%	2944
2015 Q1	$685K	Buy	109,423 +482	+0.4%	+$2.78K	﹤0.01%	2791
2014 Q4	$685K	Sell	108,941 -1,058	-1%	-$6.45K	﹤0.01%	2814
2014 Q3	$669K	Buy	109,999 +2,404	+2%	+$16.4K	﹤0.01%	2799
2014 Q2	$709K	Buy	107,595 +23,363	+28%	+$263K	﹤0.01%	2843
2014 Q1	$2.01M	Sell	84,232 -365	-0.4%	-$5.29K	﹤0.01%	2043
2013 Q4	$903K	Sell	84,597 -1,940	-2%	-$21.4K	﹤0.01%	2576
2013 Q3	$1.15M	Buy	86,537 +5,581	+7%	+$88.2K	﹤0.01%	2346
2013 Q2	$1.06M	Buy	+80,956	New	+$1.09M	﹤0.01%	2315

Other funds holding ECYT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Investment Management's ECYT Position: Q4 2016 in Review

BlackRock Investment Management held its Endocyte, Inc. Common Stock (ECYT) position steady in Q4 2016 at 159,176 shares worth $406K. The position accounts for ﹤0.01% of the portfolio, ranked #3097.

BlackRock Investment Management first reported a position in ECYT in Q2 2013 and has held it in 15 quarters since. The position peaked at $2.01M in Q1 2014. 96 funds tracked by Wall St. Rank hold ECYT as of Q4 2016.

BlackRock Investment Management held 159,176 shares of Endocyte, Inc. Common Stock worth $406K as of Q4 2016.
BlackRock Investment Management left its Endocyte, Inc. Common Stock share count unchanged in Q4 2016.
Endocyte, Inc. Common Stock made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3097 holding.
BlackRock Investment Management first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and has held it in 15 quarters since.
BlackRock Investment Management's Endocyte, Inc. Common Stock position peaked at $2.01M in Q1 2014.
96 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.